Cost‐Effectiveness of Preemptive Plerixafor Versus Rescue Plerixafor for Mobilization and Collection of Hematopoietic Stem Cells in Patients With Multiple Myeloma and Lymphoma

Documenti analoghi

• Poor Mobilization and Plerixafor Use in Matched Related Peripheral Hematopoietic Progenitor Cell Donors
  di: Elizabeth A. Godbey, et al.
  Pubblicazione: (2025)
• Preemptive Approach to Plerixafor Use Is Optimal in Patients With Relapsed/Refractory Germ Cell Tumors Undergoing Peripheral Blood Hematopoietic Stem Cell Collection: Effect on Collection Days, Yields, and Cost
  di: David O. Sohutskay, et al.
  Pubblicazione: (2024)
• Safety and Efficacy of Cyclophosphamide With Dual Mecapegfilgrastim and On‐Demand Plerixafor for Salvage Mobilization in Patients With Initial Mobilization Failure: A Retrospective Cohort
  di: Fang Huang, et al.
  Pubblicazione: (2026)
• Optimizing autologous stem cell collections for patients with multiple myeloma receiving G‐CSF and Plerixafor: A single center project
  di: Ayda Javanbakht, et al.
  Pubblicazione: (2024)
• G‐CSF Only Versus Chemotherapy and G‐CSF Peripheral Blood Stem Cell Mobilization for Autologous Hematopoietic Stem Cell Transplant—Assessing a Change in Regime due to the COVID‐19 Pandemic
  di: Julia S. Wolf, et al.
  Pubblicazione: (2025)